What is Leerink Partnrs’ Forecast for MREO Q1 Earnings?

Mereo BioPharma Group plc (NASDAQ:MREO) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Mereo BioPharma Group in a research report issued on Wednesday, March 26th. Leerink Partnrs analyst J. Schwartz anticipates that the company will post earnings per share of $0.07 for the quarter. The consensus estimate for Mereo BioPharma Group’s current full-year earnings is ($0.03) per share. Leerink Partnrs also issued estimates for Mereo BioPharma Group’s Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at $0.08 EPS and FY2026 earnings at ($0.03) EPS.

Mereo BioPharma Group (NASDAQ:MREO) last announced its quarterly earnings results on Wednesday, March 26th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.03).

Several other brokerages have also recently issued reports on MREO. Needham & Company LLC reiterated a “buy” rating and set a $7.00 price target on shares of Mereo BioPharma Group in a research report on Wednesday, March 26th. Lifesci Capital began coverage on Mereo BioPharma Group in a report on Tuesday, December 24th. They set an “outperform” rating and a $10.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 target price on shares of Mereo BioPharma Group in a research note on Tuesday, March 18th. JPMorgan Chase & Co. assumed coverage on Mereo BioPharma Group in a research report on Thursday, March 27th. They set an “overweight” rating and a $7.00 price target on the stock. Finally, Jefferies Financial Group started coverage on Mereo BioPharma Group in a report on Friday, December 6th. They issued a “buy” rating and a $7.00 price objective for the company. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $7.71.

Mereo BioPharma Group Trading Down 3.6 %

Shares of NASDAQ MREO opened at $2.17 on Monday. The firm has a fifty day simple moving average of $2.69 and a two-hundred day simple moving average of $3.45. Mereo BioPharma Group has a 12 month low of $2.11 and a 12 month high of $5.02. The firm has a market capitalization of $336.67 million, a PE ratio of -36.17 and a beta of 1.03.

Institutional Trading of Mereo BioPharma Group

Hedge funds and other institutional investors have recently made changes to their positions in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Mereo BioPharma Group during the fourth quarter valued at $3,377,000. Woodline Partners LP purchased a new position in shares of Mereo BioPharma Group in the 4th quarter worth about $2,166,000. Tema Etfs LLC bought a new position in Mereo BioPharma Group in the 4th quarter worth about $3,117,000. Janus Henderson Group PLC boosted its stake in Mereo BioPharma Group by 38.7% in the 4th quarter. Janus Henderson Group PLC now owns 17,122,563 shares of the company’s stock worth $59,843,000 after purchasing an additional 4,776,697 shares in the last quarter. Finally, Graham Capital Management L.P. grew its position in Mereo BioPharma Group by 74.7% during the 4th quarter. Graham Capital Management L.P. now owns 22,189 shares of the company’s stock valued at $78,000 after purchasing an additional 9,490 shares during the last quarter. Hedge funds and other institutional investors own 62.83% of the company’s stock.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.